



DCL:SECY:2021

12.06.2021

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400 001

National Stock Exchange of India  
Limited  
Exchange Plaza, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400 051

Scrip Code: 502137

Trading Symbol: DECCANCE

Dear Sir,

Sub: Press-release of Extract of Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021.

Please find enclosed copies of the press release dated 11<sup>th</sup> June 2021, published on 12<sup>th</sup> June 2021 on Business Standard (English – All Editions) and Andhra Prabha (Telugu- Hyderabad Edition) containing Extract of Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021 approved by the board meeting held on 11<sup>th</sup> June 2020 (Friday) *inter alia*, to consider and approve, the Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021.

Thank you,

With Regards,

For Deccan Cements Limited

Bikram Keshari Prusty  
Company Secretary



CC: Company website “ [www.deccancements.com](http://www.deccancements.com) ”

# Covaxin set for US clinical trials

FDA asks Bharat Bio's US partner Ocugen to apply for full authorisation

SOHINI DAS & RUCHIKA CHITRAVANSHI  
Mumbai/New Delhi, 11 June

Hyderabad-based Bharat Biotech will conduct clinical trials of Covaxin in the US after it hit a roadblock to secure emergency use authorisation for its Covid-19 vaccine from the US drug regulator.

The company's US partner, Ocugen, said on Thursday it would follow the biologics licence application (BLA) route to seek full licensure of Covaxin in the US.

Bharat Biotech said Ocugen had received a recommendation from the FDA to pursue BLA path for Covaxin, which is full approval. "All applications have to follow the BLA process, which is the standard process for vaccines. Therefore, for BLA, the data from an additional clinical trial will be required to support the marketing application submission for Covaxin. This process will extend our timelines," the vaccine maker said.

A company source told *Business Standard* that Bharat Biotech planned to conduct these additional clinical trials in the US. The company did not divulge details on whether these would be bridging studies comprising smaller groups of volunteers or large-scale studies.

V K Paul, member, health, NITI Aayog, said at a press briefing on Friday: "We respect their (USFDA's) decision and we expect that our manufacturer will be able to comply with whatever is required to be done. Their



## TAKING A SHOT

- Ocugen told by FDA to pursue full authorisation via BLA path
- Biologics Licence Application (BLA) a 'full approval' mechanism by the FDA for drugs and vaccines
- BLA path takes longer, stretching timeline for Covaxin's US approval
- No other Indian vaccine has full authorisation in the US

India has ever received EUA or full licensure from USFDA.

Ocugen in a statement on Thursday announced that as recommended by the USFDA, it will pursue submission of a BLA for Covaxin. Biologics Licence Application, or BLA, is a "full approval" mechanism by the FDA for drugs and vaccines. "The company will no longer pursue a EUA for Covaxin. The FDA provided feedback to Ocugen regarding the Master File. The company had previously submitted and recommended that Ocugen pursue a BLA submission instead of a EUA application for its vaccine candidate and requested additional information and data," Ocugen had said.

"Although we were close to finalising our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path. While this will extend our timelines, we are committed to bringing Covaxin to the US. This differentiated vaccine is a critical tool to include in our national arsenal given its potential to address the SARS-CoV-2 variants, including the delta variant, and given the unknowns about what will be needed to protect US population in the long term," said Shankar Musunuri, chairman, CEO and co-founder of Ocugen, had said in a statement.

Ocugen is partnering Bharat Biotech to co-develop, supply, and commercialise Covaxin in Canada. It will retain 45 per cent of the profits from sales of Covaxin in the US and Canada.

decision has no bearing on our programme. Our regulator has approved it. We have so much data on safety."

He said every country has its regulatory system and while scientific frameworks are the same, nuancing is based on context.

"Nuancing can be different, especially in countries where science is strong, for us manufacturing is strong...We have also asked for trials till now for vaccines for children."

Bharat Biotech said with good herd immunity and a significant percentage of the population vaccinated, the pandemic is reducing in the US. "The USFDA had earlier communicated that no new emergency use authorisation (EUA) would be approved for new Covid-19 vaccines," Bharat Biotech said.

According to reports, AstraZeneca is too weighing options to apply for full

approval in the US for its Covid-19 vaccine, a process that takes longer.

Timelines, however, are not clear. A senior official at a vaccine firm said there was no precedence of an India-developed vaccine getting full authorisation in the US. "Typically, the timelines would be long. It can take months or even a year. However, we cannot say if processes will be expedited during the pandemic," the official explained. Covaxin has received EUAs from 14 countries with more than 50 countries in the process. It is now in the process of seeking emergency use listing (EUL) from the World Health Organization.

Paul said the data analysis of phase 3 clinical trials of Covaxin will be made public in the next seven to eight days. "It is beyond the data that was shared with the DCGI," he added.

Bharat Biotech claimed that no vaccine manufactured or developed from

# Gati to shut 2 more businesses after cold chain exit

ADITI DIVEKAR  
Mumbai, 11 June

After exiting the cold chain business, Gati is looking to do away with two more of its subsidiaries — trading solution and freight forwarding businesses — to focus on express distribution and e-commerce.

"We are amid closing down our Gati Import Export Trading (GIETL) subsidiary, which maintains the inventory for clients on its books.

We have already dialled down all contracts under this entity and are in the process of shutting down," said Bala Aghoramurthy, deputy managing director at Gati.

According to the company's FY20 annual report, GIETL is 0.67 per cent of its consolidated net assets, which contributed a meagre ₹6.19 million to the total profits.

In May, AllCargo Group-owned Gati exited cold chain solutions business, Gati

Kausar India, to focus on the parent business and e-commerce. While the company is engaged in closing down the Gati Import Export Trading, it is in search of a suitable buyer for its freight forwarding business. "GIETL needs to be closed, but we are looking for a worthy buyer for the freight forwarding business," said Aghoramurthy.

Freight forwarding firms specialise in arranging the whole process for their

shippers, from storage to shipping of their merchandise.

It owns five fuel pumps, currently making a profit. To do away with non-core assets, it will sell these pumps and move towards becoming a core express entity.

"We have been working on the exit of Gati Kausar for the past one-and-a-half-year, from the time of acquisition. If you do not own the refrigerated business, we cannot be in the cold chain business

because the concept of leasing reefer trucks is not developed in the country. Hence, it made sense to exit this business," said Aghoramurthy.

In trucking, a reefer is a refrigerated trailer that gets attached to a semi-truck to transport perishables and other temperature-sensitive goods. Cold chain is an asset-heavy and capital-intensive business, which is against Gati's vision to move towards an asset-light company.

# Scope for steel price hike amid discount to international costs

ADITI DIVEKAR  
Mumbai, 11 June

A 20-25 per cent discount in domestic steel prices to international prices has left scope for hike in rates and a consolidated investment of ₹76,500 crore in the industry, experts said. Further, the balance sheet of the industry might lighten to a multi-year low this fiscal year, they added.

"Domestic steel prices are 20-25 per cent discount as compared to the international prices and are 15-20 per cent lower than the landed cost of imported steel. Due to this, domestic steel players continue to remain optimistic about the increase in steel prices in future as well," Brickwork Ratings said in its report. Domestic steel prices have seen an

unprecedented rise in the last few months, despite repeated lockdowns and government slashing duties, among other factors.

After remaining steady in April 2021, domestic steel prices saw another uptrend recently when the Hot/Cold Rolled Coil prices in Mumbai were revised upwards by about ₹5,000 per tonne, pushing it to a record high of about ₹70,000 and ₹83,000 per tonne, respectively, said Brickwork.

The reasons were said to be higher prices of raw materials globally and lower exports from China. With steel prices in the domestic market reaching an all-time high this year and industry capacity utilisation levels expected to inch towards 80 per cent in FY22, leading producers have announced large capex plans accumulating to 31 million tonnes, said ICRA.

**DECCAN CEMENTS LIMITED**  
CIN: L26942TG1979PLC002500  
Regd. Office: "Deccan Chambers", 6-3-666/B, Somajiguda, Hyderabad - 500 082  
Ph: 040-23310168, Fax: 040-23318366, Email: Secretariat@deccancements.com, Website: www.deccancements.com

**Extract of the Audited Financial Results for the Quarter and Year Ended 31 March 2021**  
(Rs. in Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		Audited	Unaudited	Audited	Audited	Audited
1	Total income from Operations	21383.30	20810.16	12372.22	75795.18	55533.46
2	Net Profit for the period (before Tax and Exceptional Items)	3063.49	4435.75	613.07	15536.03	6016.44
3	Net Profit for the period before tax (after Exceptional Items)	3063.49	4435.75	(349.34)	15536.03	5054.03
4	Net Profit for the period after tax (after Exceptional Items)	2207.90	3309.18	(295.58)	11512.75	5664.38
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	2202.90	3309.18	(300.64)	11507.75	5659.32
6	Paid-up Equity Share Capital	700.38	700.38	700.38	700.38	700.38
7	Earnings Per Share (Rs.5/- each)					
	1. Basic	15.76	23.62	(2.11)	82.19	40.44
	2. Diluted	15.76	23.62	(2.11)	82.19	40.44

**Notes**

a) The above results for the quarter and year ended were reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 11th June, 2021.

b) The above is an extract of the detailed format of financial results filed for the quarter and year ended 31 March 2021 with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid results are available on the Stock Exchange Websites i.e., Bombay Stock Exchange (www.bseindia.com) and National Stock Exchange (www.nseindia.com) and also on the Company's website (www.deccancements.com).

c) Figures for the last quarter are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the respective financial years.

d) The Board has recommended Final Dividend of Rs.5/- (100%) per equity shares of face value of Rs.5/- per equity share for FY 2020-21, subject to approval of the shareholders in the ensuing AGM.

for DECCAN CEMENTS LIMITED  
Sd/-  
P Parvathi  
Managing Director

Place : Hyderabad  
Date : 11-06-2021

**स्टील अथॉरिटी ऑफ इण्डिया लिमिटेड**  
**STEEL AUTHORITY OF INDIA LIMITED**  
CIN: L27109DL1973GO1006454  
REGISTERED OFFICE: ISPAT BHAWAN, LODI ROAD, NEW DELHI - 110 003  
Tel: +91-11-24367481 Fax: +91-11-24367015 E-mail: investor.relation@sail.in Website: www.sail.co.in

**Reinforcing the Vision of Atmanirbhar Bharat**

**Extract of Standalone Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021**  
(₹ in Crores unless stated otherwise)

Sl. No.	PARTICULARS	STANDALONE				
		Quarter ended		Year ended		
		31 <sup>st</sup> March, 2021	31 <sup>st</sup> Dec., 2020	31 <sup>st</sup> March, 2020	31 <sup>st</sup> March, 2021	31 <sup>st</sup> March, 2020
		Audited	Unaudited	Audited	Audited	Audited
1	Total Income from Operations	23286.00	19832.93	16171.79	69110.02	61660.55
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	4774.90	3642.43	4952.93	6820.60	3942.42
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	4608.46	3644.91	4181.17	6879.03	3170.66
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items)	3443.80	1283.17	2725.16	3850.02	2021.54
5	Total Comprehensive Income / (Loss) for the period [comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	3711.51	1293.20	2595.86	4130.55	1905.83
6	Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	4130.53	4130.53	4130.53	4130.53	4130.53
7	Reserves excluding Revaluation Reserve				39364.35	35646.85
8	Earnings per equity share (of ₹10/- each) (not annualised)					
	1. Basic (₹)	8.34	3.11	6.60	9.32	4.89
	2. Diluted (₹)	8.34	3.11	6.60	9.32	4.89

**Extract of Consolidated Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021**  
(₹ in Crores unless stated otherwise)

Sl. No.	PARTICULARS	CONSOLIDATED				
		Quarter ended		Year ended		
		31 <sup>st</sup> March, 2021	31 <sup>st</sup> Dec., 2020	31 <sup>st</sup> March, 2020	31 <sup>st</sup> March, 2021	31 <sup>st</sup> March, 2020
		Audited	Unaudited	Audited	Audited	Audited
1	Total Income from Operations	23284.89	19835.71	16171.83	69113.61	61664.16
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	4827.41	3812.20	4874.71	7147.22	4073.34
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary items)	4660.97	3814.68	4102.95	7205.65	3301.58
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary items)	3469.88	1468.20	2647.52	4148.13	2120.71
5	Total Comprehensive Income / (Loss) for the period [comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	3749.71	1431.25	2623.85	4309.03	2146.74
6	Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	4130.53	4130.53	4130.53	4130.53	4130.53
7	Reserves excluding Revaluation Reserve				41275.69	37379.70
8	Earnings per equity share (of ₹10/- each) (not annualised)					
	1. Basic (₹)	8.40	3.55	6.41	10.04	5.13
	2. Diluted (₹)	8.40	3.55	6.41	10.04	5.13

**Note:**

1) The above Financial Results have been reviewed by the Audit Committee at its meeting on 10<sup>th</sup> June, 2021 and approved by the Board of Directors at its meeting held on 10<sup>th</sup> June, 2021.

2) The above is an extract of the detailed format of Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites of NSE and BSE at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) respectively and under the Investor Relations section on the Company's website [www.sail.co.in](http://www.sail.co.in).

3) The Board of Directors has recommended final dividend @ 1.80 per equity share of Rs.10 each i.e. 18% on the paid up share capital of the company for the Financial Year 2020-21, subject to approval of the shareholders in the ensuing Annual General Meeting of the Company.

Place: New Delhi  
Dated: 10<sup>th</sup> June, 2021

For and on behalf of Board of Directors  
Sd/-  
(Amit Sen)  
Director (Finance)

*There's a little bit of SAIL in everybody's life*

Forever in our Memory

Dr. Gaur Hari Singhania

12<sup>th</sup> June, 1935 - 04<sup>th</sup> February, 2015

यद्यदाचरति श्रेष्ठस्तत्तदेवतरो जनः।  
स यत्प्रमाणं कुरुते लोकस्तदनुवर्तते॥

Whatever a great man does, the world follows.  
Whatever standards he set, the world pursues.

- Bhagwad Gita

J. K. ORGANISATION

Kamla Tower, Kanpur

Fondly remembered by family, friends and employees

